ライフサイエンスコーパス: human leukocyte antigen

1 ntigens without the need for presentation by human leukocyte antigen.

2 ntation, more patients were presensitized to human leukocyte antigens (22 [55%] vs. 4 [15%] in the ea

3 atient expressed antibody that bound all Bw4 human leukocyte antigen-A and human leukocyte antigen-B

4 All patients' results were positive for human leukocyte antigen-A29.

5 e absence of C1q-binding donor-specific anti-human leukocyte antigen alloantibody, as determined retr

6 tion studies have revealed associations with human leukocyte antigen and non-human leukocyte antigen

7 ssociation between HIV genetic variation and human leukocyte antigen and the other studying host rang

8 patients develop de novo donor-specific anti-human leukocyte antigen antibodies (dnDSA) after transpl

9 Although preformed donor-specific anti-human leukocyte antigen antibodies (DSA) can be overcome

10 Monitoring anti-human leukocyte antigen antibodies after cellular reject

11 en bead (SAB) assay measuring C1q binding to human leukocyte antigen antibodies has recently been int

12 Serologic determination of human leukocyte antigen antibodies showed higher positiv

13 Anti-human leukocyte antigen antibodies were analyzed before

14 3%) of the 1,974 C1q-negative SABs contained human leukocyte antigen antibodies with strong complemen

15 nor age, human leukocyte antigen mismatches, human leukocyte antigen antibodies, cold ischemia time,

16 d Medicaid Services to evaluate whether anti-human leukocyte antigen antibodies, measured as panel re

17 transplant recipients have pre-existing anti-human leukocyte antigen antibodies.

18 HTX) may be limited by the formation of anti-human leukocyte antigen antibodies.

19 Sensitization was defined as peak anti-human leukocyte antigen antibody values of more than 200

20 used in transplantation settings to deplete human leukocyte antigen antibody-producing plasma cells

21 ted with HIV/Mtb had decreased expression of human leukocyte antigen antigen D related and the costim

22 ytokine production and significantly reduced human leukocyte antigen - antigen D related expression.

23 e response to bacterial stimulation and less human leukocyte antigen - antigen D related.

24 d in peripheral blood mononuclear cells, and human leukocyte antigen-antigen D related expression on

25 reexisting donor-specific antibodies against human leukocyte antigens are major risk factors for acut

26 cially of activated drug-reacting T cells in human leukocyte antigen-associated, drug-induced liver i

27 atic T-cell infiltrates and a strong genetic human leukocyte antigen association represent characteri

28 bound all Bw4 human leukocyte antigen-A and human leukocyte antigen-B antigens tested, except B*27:0

29 Human leukocyte antigen-B40 group and HLA-B8 were identi

30 ed using the highly sensitive single-antigen human leukocyte antigen bead assay 5.1 +/- 3.9 months af

31 sed strategy relies on initial prediction of human leukocyte antigen-binding peptides by in silico al

32 However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell recept

33 Human leukocyte antigen class I (HLA)-restricted CD8(+)

34 /= 40 years, adjusted P = 0.010) and several human leukocyte antigen class I (HLA-I) alleles, includi

35 efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules.

36 cells before Nef-mediated downregulation of human leukocyte antigen class I (HLA-I).

37 Purified anti-human leukocyte antigen class I antibody (W6/32), isotyp

38 h-throughput 13-parameter flow cytometry and human leukocyte antigen class I cytomegalovirus-specific

39 Invading placental trophoblast cells express human leukocyte antigen class I ligands (HLA-E, HLA-G, a

40 Analysis of immune responses ex vivo used human leukocyte antigen class I pentamers, intracellular

41 c flow cytometry with ultrasensitive peptide-human leukocyte antigen class I tetramer staining to qua

42 CD133, and c-Met and the immunologic markers human leukocyte antigen class II and programmed death li

43 igen antibodies showed higher positivity for human leukocyte antigen class II donor-specific antibodi

44 y history of type 1 diabetes and susceptible human leukocyte antigen class II genotypes.

45 triggered by an interaction between gp42 and human leukocyte antigen class II.

46 Here, we report the ability of accepting human leukocyte antigen-compatible but ABO-incompatible

47 e system through their interactions with the human leukocyte antigen complex, and neoantigen presence

48 tages of circulating activated CD4+ T cells (human leukocyte antigen-D related [HLA-DR]+CD38+CD4+) (f

49 ients' monocytes expressed reduced levels of human leukocyte antigen-D-related peptide and released l

50 Monocyte expression of human leukocyte antigen-D-related peptide, sol-tumor nec

51 tologous therapy or, alternatively, banks of human leukocyte antigen diverse iPSCs are possible for a

52 The human leukocyte antigen DQB1*06:02 was absent in all pat

53 red susceptibility genes, HLA-DRbeta1-Arg74 (human leukocyte antigen DR containing an arginine at pos

54 h lymphoproliferation and Treg generation in human leukocyte antigen DR matched and mismatched MLRs e

55 tiation 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline.

56 reas levels of macrophage-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increase

57 down-regulated macrophage-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated po

58 n of the ocular surface inflammatory markers human leukocyte antigen-DR (HLA-DR) and intercellular ad

59 6, but both demonstrated increased levels of human leukocyte antigen-DR (HLA-DR) following IFN-gamma

60 cyte cluster of differentiation 163 (CD163), human leukocyte antigen-DR (HLA-DR), and lipopolysacchar

61 onoclonal antibodies against CD14, CD16, and human leukocyte antigen-DR (HLA-DR), and subjected to fl

62 We found a profound decrease in human leukocyte antigen-DR on Mo and DCs in burned patie

63 The expression of human leukocyte antigen-DR was determined on all DCs and

64 expansion of suppressive CD25(high)CD127(low)human leukocyte antigen-DR(+)FoxP3(high) effector regula

65 Granzyme B), CD68 (macrophages), and HLA-DR (human leukocyte antigen-DR) antigens (activation marker)

66 plex class II (MHC II) and instead expresses human leukocyte antigen DR1 (HLA-DR1).

67 rapy and an association with the presence of human leukocyte antigen-DR15 were found.

68 ecognized in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 transgenic mice, ind

69 mplex class II antigen was replaced with the human leukocyte antigen DR4 (HLA-DR4).

70 Lo Monaco et al. propose that human leukocyte antigen E (HLA-E) and HLA-C expression l

71 PPCLs uniformly expressed class I human leukocyte antigen, epithelial cell adhesion molecu

72 ulated sidedness dependent differential hMSC human leukocyte antigen expression, angiogenic and infla

73 ocompatibility complex (MHC) molecule HLA-F (human leukocyte antigen F) regulates the immune system i

74 atural immune tolerance mechanism induced by human leukocyte antigen G (HLA-G), was investigated.

75 ual member of the KIR family that recognizes human leukocyte antigen G and mediates NK-cell activatio

76 Functional assays indicated that human leukocyte antigen G, the preferred ligand of ILT4,

77 Consequently to this ILT4 up-regulation, the human leukocyte antigen G-mediated inhibition of neutrop

78 Human leukocyte antigen-G (HLA-G) is a nonclassical majo

79 irects differentiation preferentially toward human leukocyte antigen-G(+) pcEVT, and that an intact H

80 or receptor(+) villous cytotrophoblasts into human leukocyte antigen-G(+) proximal column EVT (pcEVT)

81 Invading human leukocyte antigen-G+ (HLA-G+) extravillous trophob

82 terleukin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561

83 Fast-Pairwise successfully fine-maps a known human leukocyte antigen gene that is known to cause the

84 However, the functional relationship between human leukocyte antigen gene(s) and disease development

85 iations with human leukocyte antigen and non-human leukocyte antigen genes of 3 major histocompatibil

86 r of interactions among different classes of human leukocyte antigen genes that may interact to influ

87 e in the child after adjustment for country, human leukocyte antigen genotype, family history of celi

88 nsitivity and specificity, and by estimating human leukocyte antigen genotypes directly from variant

89 ,208 Graves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-

90 Today human leukocyte antigen-haploidentical transplantation i

91 th acute lymphoblastic leukemia who received human leukocyte antigen-haploidentical transplantation o

92 The present review describes the biology of human leukocyte antigen haplotype mismatched ("haploiden

93 The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute c

94 VDSLFFL (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recogn

95 high-risk stage III melanoma were grouped by human leukocyte antigen (HLA) -A2 status.

96 approaches in a multi-institutional study of human leukocyte antigen (HLA) -matched bone marrow trans

97 Balancing selection has maintained human leukocyte antigen (HLA) allele diversity, but it i

98 The expense of human leukocyte antigen (HLA) allele genotyping has moti

99 dentifies new associations between classical human leukocyte antigen (HLA) alleles and common immune-

100 efore searched for genetic associations with human leukocyte antigen (HLA) alleles and IFN-lambda3 ge

101 Despite progress in defining human leukocyte antigen (HLA) alleles for anti-citrullin

102 Specific human leukocyte antigen (HLA) alleles have been identifi

103 tly, we detected the involvement of the same human leukocyte antigen (HLA) alleles in both SCZ and MS

104 aginase-induced immune responses, we imputed human leukocyte antigen (HLA) alleles in patients of Eur

105 e impact of source partner HIV-1 RNA levels, human leukocyte antigen (HLA) alleles, and innate respon

106 enome-wide association study (GWAS), imputed human leukocyte antigen (HLA) alleles, exome array and c

107 sture disease, is associated with particular human leukocyte antigen (HLA) alleles.

108 We performed human leukocyte antigen (HLA) analysis in 25 nontumor an

109 to multiplexed flow cytometry-recorded anti-human leukocyte antigen (HLA) and anti-MICA antibodies o

110 ze peptide- and lipid-based Ags presented by human leukocyte antigen (HLA) and CD1d, respectively.

111 say, with high sensitivity in detecting anti-human leukocyte antigen (HLA) antibodies (Abs), have inc

112 ce and impact of de novo donor-specific anti-human leukocyte antigen (HLA) antibodies (dnDSA) in the

113 retransplantation strong donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) are at hi

114 De novo donor-specific human leukocyte antigen (HLA) antibodies (DSA) posttrans

115 We examined the appearance of human leukocyte antigen (HLA) antibodies after withdrawa

116 gy for the detection and characterization of human leukocyte antigen (HLA) antibodies in transplantat

117 iovascular risk factors and circulating anti-human leukocyte antigen (HLA) antibodies.

118 Safety was also evaluated by measuring anti-human leukocyte antigen (HLA) antibodies.

119 tric kidney recipients monitored for de novo human leukocyte antigen (HLA) antibody (Ab) occurrence t

120 mine the incidence of de novo donor-specific human leukocyte antigen (HLA) antibody (dnDSA) during th

121 increase the specificity and sensitivity of human leukocyte antigen (HLA) antibody detection assays

122 Anti-human leukocyte antigen (HLA) antibody detection in soli

123 f sensitization a patient might have against human leukocyte antigen (HLA) antigens.

124 10(-9)) and confirm the previously reported human leukocyte antigen (HLA) associations on chromosome

125 xemplified by several key examples and their human leukocyte antigen (HLA) associations: abacavir and

126 for recurrence was higher for patients with human leukocyte antigen (HLA) B49 (odds ratio, 16.9; 95%

127 Despite the progress in human leukocyte antigen (HLA) causal variant mapping, in

128 The human leukocyte antigen (HLA) class I allele, HLA-C*06:0

129 ility complex (MHC) containing the classical human leukocyte antigen (HLA) Class I and Class II genes

130 The development of donor-specific human leukocyte antigen (HLA) class I antibodies after o

131 Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause th

132 ct the natural history of HIV infection, the human leukocyte antigen (HLA) class I genes exhibit the

133 Here we investigate the role of the human leukocyte antigen (HLA) class I genes in this biol

134 patients with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B

135 The identification of peptides presented by human leukocyte antigen (HLA) class I is tremendously im

136 Possession of the human leukocyte antigen (HLA) class I molecule B27 is st

137 erexpression down-regulates the nonclassical human leukocyte antigen (HLA) class I molecule HLA-G in

138 ented on tumors and not on normal tissues by human leukocyte antigen (HLA) class I molecules are prom

139 Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind to

140 f tumor-specific antigens improves access to human leukocyte antigen (HLA) class I molecules for more

141 Human leukocyte antigen (HLA) class I molecules generall

142 sentation of short viral peptide antigens by human leukocyte antigen (HLA) class I molecules on cell

143 lin-like receptors (KIR) which interact with human leukocyte antigen (HLA) class I molecules on targe

144 oteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that eli

145 ion of several LRC products with polymorphic human leukocyte antigen (HLA) class I molecules.

146 lved two broad strategies for recognition of human leukocyte antigen (HLA) class I molecules: (i) dir

147 dissect the link between hyperexpression of human leukocyte antigen (HLA) class I on the islet cells

148 Humanized mice expressing Human Leukocyte Antigen (HLA) class I or II transgenes h

149 Human leukocyte antigen (HLA) class I presents viral pep

150 its targeted capacity to selectively remove human leukocyte antigen (HLA) class I proteins from dono

151 Human leukocyte antigen (HLA) class I-associated polymor

152 s spectrometric observations of glycosylated human leukocyte antigen (HLA) class I-bound peptides.

153 hese cells, thus enabling their evasion from human leukocyte antigen (HLA) class I-restricted CD8(+)

154 genome that allow it to escape detection by human leukocyte antigen (HLA) class I-restricted immune

155 immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoanti

156 tin (orexin), is so strongly associated with human leukocyte antigen (HLA) class II HLA-DQA1( *)01:02

157 Here, we demonstrate the presence of human leukocyte antigen (HLA) class II-restricted CD8(+)

158 er immunoglobulin-like receptors (KIRs) bind human leukocyte antigen (HLA) class-I (HLA-I) ligands an

159 ies have emphasized ethnically heterogeneous human leukocyte antigen (HLA) classical allele associati

160 The immunoregulatory human leukocyte antigen (HLA) complex has been linked to

161 omplex (MHC) protein which is encoded by the human leukocyte antigen (HLA) complex.

162 f pretransplant antibodies directed at donor human leukocyte antigen (HLA) donor-specific antibodies

163 ed 1679 Dutch children who were positive for human leukocyte antigen (HLA) DQ2/DQ8.

164 ients with ABMR associated with de novo anti-human leukocyte antigen (HLA) DSA.

165 which is currently achieved by matching for human leukocyte antigen (HLA) expression, immunosuppress

166 lar lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants.

167 Variation in the human leukocyte antigen (HLA) genes accounts for one-hal

168 Human leukocyte antigen (HLA) genes confer substantial r

169 European descent by imputing class I and II human leukocyte antigen (HLA) genes from SNP genotype da

170 he understanding of how variation within the human leukocyte antigen (HLA) genes influences risk of m

171 st polymorphic genetic system in humans, the human leukocyte antigen (HLA) genes of the adaptive immu

172 IRF7, NOTCH4, PLAUR, CSK, IRAK1, and several human leukocyte antigen (HLA) genes.

173 95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR,

174 ell killer immunoglobulin-like receptors and human leukocyte antigen (HLA) genotype with risk of CMV

175 lar support has been provided by analysis of human leukocyte antigen (HLA) haplotypes and genome-wide

176 the tight association of narcolepsy with the human leukocyte antigen (HLA) HLA-DQB1*06:02 allele, we

177 transplantation consider information at the human leukocyte antigen (HLA) loci.

178 g the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune

179 Our aim was to identify predictive human leukocyte antigen (HLA) markers that are associate

180 The effect of donor-recipient human leukocyte antigen (HLA) matching on outcomes remai

181 ounger donors and shorter waiting times over human leukocyte antigen (HLA) matching.

182 incidence of AE increased with the number of human leukocyte antigen (HLA) mismatches (18%, 10%, and

183 Human leukocyte antigen (HLA) mismatches are known to in

184 Then, three decades ago, an unusual human leukocyte antigen (HLA) molecule was identified: H

185 sented on the cell surface in the context of human leukocyte antigen (HLA) molecules have been target

186 receptors (KIRs) with their target ligands, human leukocyte antigen (HLA) molecules, is a critical c

187 , including the antigen-presenting classical human leukocyte antigen (HLA) molecules.

188 des with high-affinity binding of autologous human leukocyte antigen (HLA) molecules.

189 the binding preferences of the best-matched Human Leukocyte Antigen (HLA) pocket for each SLA pocket

190 diverse T cell repertoire and the extensive human leukocyte antigen (HLA) polymorphism across popula

191 f the host, and is linked to their allele of human leukocyte antigen (HLA) proteins, which present pr

192 loring additional susceptibility loci in the human leukocyte antigen (HLA) region are complicated by

193 In addition to strong association within the human leukocyte antigen (HLA) region at 6p21 (Pmeta = 7.

194 Additionally, the human leukocyte antigen (HLA) region was comprehensively

195 es, amino acid residues, and SNPs across the human leukocyte antigen (HLA) region were imputed and te

196 geal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA

197 ed association of 3 known JIA risk loci (the human leukocyte antigen (HLA) region, PTPN22 and PTPN2)

198 g heritability of IQ might lie hidden in the human leukocyte antigen (HLA) region, which plays a crit

199 rin gene, the C11orf30/LRRC32 locus, and the human leukocyte antigen (HLA) region.

200 ping and imputation was used to fine-map the human leukocyte antigen (HLA) region.

201 wide association studies and SNPs within the human leukocyte antigen (HLA) region.

202 Patterns of human leukocyte antigen (HLA) restriction of immunodomin

203 In addition, human leukocyte antigen (HLA) serotypes were also impute

204 ipient suitability for HSCT is determined by Human Leukocyte Antigen (HLA) similarity.

205 Human leukocyte antigen (HLA) supertypes are groups of f

206 Genes of the human leukocyte antigen (HLA) system encode cell-surface

207 on of high sequence divergence harboring the human leukocyte antigen (HLA) system, we found that loca

208 The purpose of this study was to identify human leukocyte antigen (HLA) type as risk and prognosti

209 Advancements in human leukocyte antigen (HLA) typing and supportive care

210 Human leukocyte antigen (HLA) typing at the allelic leve

211 on Workflow Language (CWL) implementation of human leukocyte antigen (HLA) typing using Polysolver or

212 Two human leukocyte antigen (HLA) variants, HLA-B*57 and -B*

213 Newborn screening for human leukocyte antigen (HLA) was done at St. Joseph's H

214 helial in vitro model of ABMR due to class I human leukocyte antigen (HLA) with and without complemen

215 unique peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were

216 Aggregate morphologies also influence Human Leukocyte Antigen (HLA)--types recognized by the a

217 udied the effect of allele-level matching at human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 in 15

218 d-donor kidney allocation considers only the human leukocyte antigen (HLA)-A, HLA-B, and HLA-DR loci.

219 cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to i

220 eactive CD8(+) T cells in situ, in islets of human leukocyte antigen (HLA)-A2(+) donors and isolation

221 pitope KK10 (KRWIILGLNK263-272) presented by human leukocyte antigen (HLA)-B *2705.

222 s located in one of the putative epitopes of human leukocyte antigen (HLA)-B*18-restricted cytotoxic

223 in the reaction onset and identification of human leukocyte antigen (HLA)-B*57:01 as a susceptibilit

224 Consecutive patients with AU who were human leukocyte antigen (HLA)-B27 positive or HLA-B27 ne

225 Identification of human leukocyte antigen (HLA)-bound peptides by liquid c

226 Human leukocyte antigen (HLA)-C*06:02 is identified as t

227 all studies suggest that the presence of the human leukocyte antigen (HLA)-Cw6 (C*06:02) allele may b

228 Human leukocyte antigen (HLA)-DQ has emerged as the allo

229 6 mo of age in 715 children positive for the human leukocyte antigen (HLA)-DQ2 and/or HLA-DQ8 from 5

230 Human leukocyte antigen (HLA)-DQ2.5 (DQA1*05/DQB1*02) is

231 ntified T-cell epitopes presented in vivo by human leukocyte antigen (HLA)-DR molecules in patients'

232 ratio [OR], 7.07; P < .05), the presence of human leukocyte antigen (HLA)-DR7 (OR, 5.65; P < .05), a

233 cytokine levels and number of copies of the human leukocyte antigen (HLA)-DRB1 (HLA-DRB1) shared epi

234 studies have reported an association between human leukocyte antigen (HLA)-DRB1 and the risk of PD.

235 Specific alleles of the human leukocyte antigen (HLA)-DRB1 gene (HLA-DRB1) encod

236 thritis (RA) is strongly associated with the human leukocyte antigen (HLA)-DRB1 locus that possesses

237 onse restricted by the human MHC-Ib molecule human leukocyte antigen (HLA)-E and specific for an epit

238 The banking of human leukocyte antigen (HLA)-homozygous-induced pluripo

239 Human leukocyte antigen (HLA)-I molecules can present lo

240 For patients who do not have a suitable human leukocyte antigen (HLA)-matched family donor, unre

241 Human leukocyte antigen (HLA)-matched sibling donor (MSD

242 We wanted to find out whether a male human leukocyte antigen (HLA)-matched unrelated donor (M

243 The role of B-cell subsets in human leukocyte antigen (HLA)-specific humoral responses

244 A mouse model of human leukocyte antigen (HLA).A2 sensitization was used

245 of antinuclear antibodies (ANA), presence of human leukocyte antigen (HLA-)B27, age of onset of JIA,

246 -1 gB, gD, VP11/12, and VP13/14 proteins, in human leukocyte antigen (HLA-A*0201) transgenic rabbits

247 ole attributed to the genes encoding class I human leukocyte antigens (HLA) and the chemokine recepto

248 er immunoglobulin-like receptors (KIRs), and human leukocyte antigens (HLA) class I molecules.

249 We utilized mice transgenic for human leukocyte antigens (HLA) lacking the alpha/beta in

250 re epitopes presented to CTLs by the class I human leukocyte antigens (HLA) of infected cells.

251 ta (alleles, genes or haplotypes) related to human leukocyte antigens (HLA), killer-cell immunoglobul

252 s6457327-by measuring their correlation with human-leukocyte-antigen (HLA) expression levels obtained

253 hods developed for other complex loci (e.g., human leukocyte antigen [HLA]) on the basis of SNP data

254 ctivated and mobilized within immunodominant human-leukocyte-antigen-(HLA)-A*11:01-restricted CD8(+)

255 Understanding the binding between human leukocyte antigens (HLAs) and peptides is importan

256 Human leukocyte antigens (HLAs) are a basic precondition

257 tocompatibility complex (MHC), which encodes human leukocyte antigens (HLAs) in humans.

258 of pre-formed antibodies to population-wide human leukocyte antigens (HLAs) in patients being evalua

259 ant antibodies recognizing denatured class I human leukocyte antigens (HLAs).

260 region harboring genes encoding the class II human leukocyte antigens (HLAs): rs557011[T] (minor alle

261 alid transplant options for patients without human leukocyte antigen-identical sibling or match unrel

262 e serum decreased lipid uptake and increased human leukocyte antigen II (HLA II) expression.

263 ents transplanted with a positive crossmatch human leukocyte antigen-incompatible kidney between 2000

264 ents transplanted with a positive crossmatch human leukocyte antigen-incompatible kidney between 2000

265 occurred in this subset of closely monitored human leukocyte antigen-incompatible recipients througho

266 occurred in this subset of closely monitored human leukocyte antigen-incompatible recipients througho

267 associations to genetic variants, including human leukocyte antigen loci with carbamazepine-induced

268 c hypomethylation of the region encoding the human leukocyte antigen locus (HLA).

269 nnective tissue disorder associated with the human leukocyte antigen locus.

270 Here, we present loss of heterozygosity in human leukocyte antigen (LOHHLA), a computational tool t

271 two defined pre-transplant characteristics: human leukocyte antigen match (10/10 versus <10/10) and

272 cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double

273 ge to the recipient (younger donor or better human leukocyte antigen match), whereas delays beyond 3

274 T), whereas others may not have a compatible human leukocyte antigen-matched donor.

275 ntributed information on 2985 patients given human leukocyte antigen-matched grafts to address this q

276 a first hematopoietic cell transplant from a human leukocyte antigen-matched sibling or from an unrel

277 stem cells (5.5-31.7 x 10(6) cells/kg) from human leukocyte antigen-matched siblings.

278 Molecular techniques have allowed for better human leukocyte antigen matching of unrelated adult dono

279 or early BCAR+BL and CSWD (HR, 1.9; P<0.02), human leukocyte antigen mismatch (HR, 1.2; P<0.01), and

280 CSWD (hazard ratio [HR], 4.72; P<0.002) and human leukocyte antigen mismatch (HR, 1.48; P<0.005) for

281 Human leukocyte antigen mismatch number (hazards ratio,

282 recipient and donor characteristics, such as human leukocyte antigen mismatch, age, and use of antith

283 BO-compatible controls by age, gender, race, human leukocyte antigen mismatch, retransplantation, and

284 raoperative blood transfusions, reoperation, human leukocyte antigen mismatch, use of nonstandard imm

285 ATG) to mixed lymphocyte co-cultures between human leukocyte antigen-mismatched peripheral blood lymp

286 20%; the two groups differed with respect to human leukocyte antigen mismatches (4.7 +/- 1.1 vs. 4.1

287 0.002) in the adjusted models independent of human leukocyte antigen mismatches and initial immunosup

288 ancreas recipient, and increasing numbers of human leukocyte antigen mismatches were independent risk

289 age, basiliximab induction, sex, donor age, human leukocyte antigen mismatches, human leukocyte anti

290 We show that both alleles of genes encoding human leukocyte antigen molecules and genes encoding com

291 The HLA (human leukocyte antigen) molecules that present pathogen

292 We used yeast-display libraries of peptide-human leukocyte antigen (pHLA) to screen for antigens of

293 nd activated C3 localized at synapses within human leukocyte antigen-positive cell processes and lyso

294 tide polymorphism rs41269979 in the class II human leukocyte antigen region was more frequent in the

295 ping analysis to dissect associations in the human leukocyte antigen region, which suggests important

296 age, rank of transplantation, and absence of human leukocyte antigen sensitization.

297 clonotypes were detected among patients with human leukocyte antigen susceptibility alleles.

298 nk between donor-specific antibodies against human leukocyte antigens type II (DSA II+) and transplan

299 and ALD (n = 10) patients, alongside genomic human leukocyte antigen typing.

300 e human tumor antigen NY-ESO-1 (ESO) and the human leukocyte antigen variant HLA-A*0201 (A2) as a mod